The importance of CD4+ T cells in a tumor immune response is gaining acceptance (108), and clinical trials and syngeneic mouse model studies have similarly identified distinct immune correlates (53, 54, 94, 109, 110). The gene discussed is CD4; the disease is neoplasm.